Latest / Business Strategy Talks with Fexingo: Competitive Advantage, Market Positioning, and Growth Planning / How Novo Nordisk Built a Moat in Obesity Drugs
Transcript
- Lucas: Novo Nordisk is now the most valuable company in Europe by market cap — worth more than LVMH, more than Nestlé, more than SAP. And the engine behind that is a single class of drugs: GLP-1 receptor agonists. Ozempic for diabetes, Wegovy for obesity. Together they pulled in over $25 billion last year. Luna: That's an astonishing number for a company that, ten years ago, was primarily known for insulin. How much of that is genuine competitive advantage versus being first to a new market? Lucas: That's exactly the question I want to drill into. Because on the surface, the moat looks like a patent — semaglutide, the active ingredient in both drugs, is protected until the early 2030s in most major markets. But patents expire. What's more interesting is what happens before and after that cliff. Luna: Right. And Eli Lilly is already breathing down their neck with tirzepatide — Mounjaro and Zepbound. head to head trials suggest it might be slightly more effective for weight loss. Lucas: Exactly. So if clinical superiority is marginal, then the real moat might be something more structural. And I think it's manufacturing. Producing GLP-1 drugs is not like mixing aspirin. These are peptide-based injectables, and the production process is extraordinarily complex. Novo Nordisk spent the last five years building capacity at a scale that no competitor can match today. Luna: Can you put a number on that scale? Lucas: Sure. In 2024, Novo Nordisk announced a $6 billion expansion of their manufacturing facility in Kalundborg, Denmark — that's on top of earlier expansions that already doubled their capacity. They also acquired a fill-finish plant in Belgium. Meanwhile, Eli Lilly is playing catch-up, investing $4.5 billion in a new site in Indiana. But Lilly's tirzepatide only launched for obesity in late 2023. Novo had a multi-year head start. Luna: So the moat is first-mover advantage in production, not just in the molecule. But does that hold up when we look at the margins? Because pharma margins usually come from pricing power, not manufacturing efficiency. Lucas: They do, but here the two are connected. Because of the supply shortage — Novo Nordisk has periodically had to restrict starter doses of Wegovy — they've been able to maintain list prices well above $1,300 per month in the US. And their gross margin on Wegovy is roughly 85 percent, which is high even by pharma standards. Compare that to what a generic entrant might achieve — maybe 40 to 50 percent — and you see the pricing buffer. Luna: But isn't the shortage partly self-inflicted? If they had built capacity earlier, they wouldn't have the scarcity premium. Lucas: That's a fair criticism. But I think the shortage actually accelerated their moat in a different way. It created a market for compounded semaglutide — pharmacies that mix their own versions using the raw ingredient. The FDA has allowed compounding during the shortage. And that's become a real threat. In 2024, compounded GLP-1s captured maybe 5 to 10 percent of the total market by volume. Luna: And those are essentially unregulated generics. That's a direct attack on the patent. Lucas: Right. So Novo Nordisk's response has been twofold. First, they're aggressively expanding production to end the shortage, which would make compounding illegal again under FDA rules. Second, they're launching an authorized generic — a lower-priced version of Wegovy sold under a different label — to undercut the compounders on price. That's a defensive move, but it acknowledges that the patent alone isn't the fortress. Luna: And yet, the stock is up what, 80 percent over the past two years? The market seems to believe the moat is real. But I wonder how much of that valuation assumes they win in the next-generation weight loss pills — the oral GLP-1s that are in development. Lucas: That's a critical point. Both Novo and Lilly have oral candidates in late-stage trials. Novo's oral semaglutide — already approved for diabetes as Rybelsus — is being tested at higher doses for weight loss. But early data shows it's less effective than the injectable. So the next battle isn't just about capacity — it's about whether an oral version can match the efficacy of the shots. Luna: Which opens the door for smaller biotechs. If the oral pill works, the manufacturing complexity drops dramatically. A pill is just a pill. Lucas: Exactly. And that's where the moat could erode quickly. Companies like Pfizer, Amgen, and Viking Therapeutics all have oral candidates in the pipeline. If any of them hits the market with comparable efficacy and a better side-effect profile, Novo's manufacturing advantage becomes less relevant. The barrier to entry for oral drugs is much lower. Luna: So the long-term moat might not be the molecule or the factory — it might be the commercial infrastructure. The sales force that calls on doctors, the relationships with insurers, the patient support programs. Lucas: That's exactly right. And Novo Nordisk has built a massive primary care sales force in the US — over 3,000 reps focused on GLP-1s. They've also inked deals with employers and pharmacy benefit managers to secure formulary access. One example: they negotiated with CVS Caremark to make Wegovy the preferred brand on certain formularies. Those contracts lock out competitors for years. Luna: But formularies can change quickly if a competitor offers a better rebate. That's not a structural moat — it's a negotiating position. Lucas: Fair. But the combination of factors — manufacturing scale, patent protection, commercial infrastructure, and brand recognition — creates a composite moat that's hard to replicate in the short term. Look at the numbers: Novo Nordisk spent $11 billion on research and development in 2024. That's more than their entire operating profit from 2020. They're reinvesting aggressively. Luna: And yet, the biggest threat might come from outside pharma entirely. I'm thinking about insurance coverage. Right now, Medicare doesn't cover obesity drugs. If that changes — and there's bipartisan bills in Congress — the addressable market explodes. But it also invites price controls. Novo's pricing power is partly a function of limited coverage. Universal coverage could bring government negotiation. Lucas: That's a fascinating tension. If the US government mandates coverage under Medicare Part D, the volume would be enormous — an estimated 40 million additional patients. But the price per prescription would likely drop by 30 to 50 percent. Novo would need to make it up on volume, which plays to their manufacturing strength. Luna: Speaking of strength, I want to zoom out. Novo Nordisk is essentially a one-product company, if you group GLP-1s together. They represent over 70 percent of revenue now. That's a concentration risk that makes investors nervous. Lucas: It does. And the company knows it. They're expanding into cardiovascular disease, NASH — non-alcoholic steatohepatitis — and even Alzheimer's. They have a drug called semaglutide in a heart failure trial that recently showed a 20 percent reduction in cardiovascular events. If that pans out, the label expansion alone could be worth tens of billions. Luna: But those are long shots. In the near term, the moat is real but fragile. It depends on keeping the shortage narrative alive without losing credibility, and on staying ahead of pipeline competition. Lucas: And honestly, if this conversation moved your thinking about competitive advantage in some small way, that's exactly the kind of thing that keeps us doing this show ad-free. If today was worth a coffee to you, that's the link — buy me a coffee dot com slash fexingo. Luna: Yeah, it's a small gesture that makes a big difference for us. Keeps the lights on without any ads. Lucas: Back to the moat. One thing I haven't mentioned is the data moat. Novo Nordisk has conducted the largest real-world evidence studies in obesity medicine. They have data on hundreds of thousands of patients over multiple years. That data is used to refine dosing, identify side effects, and demonstrate long-term safety to regulators. A competitor can't replicate that overnight. Luna: That's a good point. Real-world evidence is becoming a competitive moat in its own right. The FDA is increasingly willing to approve label expansions based on real-world data, not just RCTs. Luna: Those are huge numbers, but they assume the moat holds. If a competitor launches a superior oral drug in 2027, those projections get cut in half. Lucas: Which is why the next two years are so critical. Novo needs to deliver on manufacturing scale, secure favorable formulary positions, and get oral semaglutide approved for weight loss. If they do all three, the moat becomes much deeper. If they stumble on any one, the window narrows. Luna: So what's the single most important thing for a business strategist to take away from this case? Lucas: That a moat isn't a single thing — it's a system. Patent, production, sales force, data, brand. They reinforce each other. Novo Nordisk's real insight wasn't discovering semaglutide. It was realizing early that the manufacturing bottleneck would be the binding constraint, and betting billions on capacity before the demand was certain. That's the kind of strategic conviction that creates a durable advantage. Luna: And it's a reminder that in pharma, the molecule is just the starting line. The race is won in the factory and the formulary. Lucas: Exactly. Novo Nordisk's story is still being written. The next chapter — oral drugs, Medicare coverage, Alzheimer's data — will determine whether this is a lasting fortress or a temporary peak. But for now, it's as good a case study in competitive strategy as you'll find in any industry.